Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
Open Access
- 12 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-12
- https://doi.org/10.1038/s41598-021-81415-0
Abstract
To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.This publication has 30 references indexed in Scilit:
- Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patientsRespirology, 2016
- Bloodstream Infections in Patients With Solid TumorsMedicine, 2014
- Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adultsVaccine, 2014
- Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumoniaThorax, 2013
- Factors associated with mortality in bacteremic patients with hematologic malignanciesDiagnostic Microbiology and Infectious Disease, 2009
- Streptococcus pneumoniae Bacteremia in Patients With CancerMedicine, 2005
- Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002)Diagnostic Microbiology and Infectious Disease, 2004
- Bacteremic Pneumonia in Neutropenic Patients With CancerArchives of Internal Medicine, 1998
- Pneumococcal bacteremia in cancer patientsEuropean Journal of Epidemiology, 1988
- Polymicrobial Septicemia in the Cancer PatientMedicine, 1986